Wilfully and ignoring facts is what you seems to specialize in RBX not me.
"CanTx and Novogen expect to file an Investigational New Drug (IND) application for Cantrixil early next year and to advance this compound into the clinic by mid- 2015."
"This is an exciting path that we are now on," Dr. Kelly continued. "The manufacturing programs currently underway will furnish us with sufficient drug to complete the IND process and to undertake Phase 1 studies in patients with late-stage ovarian cancer in 2015."
